Evidence map›Paper›PMID 39316291›Full record

ArticleAdvances in therapy2024

Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China.

Shun Lu, Lan Shen, Qiming Wang, Haiyang Chen, Yi Zhao, Ying Li, Grace Segall, Manoj Khanal, Xue Zhang, Ding Ding and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shun LuDepartment of Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200000, China. shun.lu@me.com.
Lan ShenDepartment of Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, 241 Huaihai West Road, Shanghai, 200000, China.
Qiming WangDepartment of Oncology, Henan Cancer Hospital, Zhengzhou, China.
Haiyang ChenDepartment of Oncology, Henan Cancer Hospital, Zhengzhou, China.
Yi ZhaoDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Ying LiDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Grace SegallEli Lilly and Company, Bracknell, UK.
Manoj KhanalEli Lilly and Company, Indianapolis, IN, USA.
Xue ZhangEli Lilly and Company, Shanghai, China.
Ding DingEli Lilly and Company, Shanghai, China.
Jingxin ShaoEli Lilly and Company, Shanghai, China.
Long PangReal-World Solutions, IQVIA, Shanghai, China.

Funding

LOXO-292:China-Patient characteristics and treatment patterns in patients with RET fusion positive NSCLC 2020-9554
6 · The paper itself

Abstract

introductionEpidemiological studies on non-small cell lung cancer (NSCLC) have noted RET fusions as an oncogenic driver. However, real-world data on RET biomarker testing and treatment patterns in China remain limited. This study aimed to examine demographics, clinical and molecular features, and RET testing and treatment patterns and outcomes in patients with RET fusion-positive NSCLC.

methodsUtilizing real-world data from the Chinese Multi-center Lung Cancer Precision Medicine Registry, this retrospective cohort study focused on Chinese patients diagnosed with RET fusion-positive NSCLC between January 1, 2016, and November 30, 2021. The cohort was divided into early-stage and advanced-stage subgroups. Demographics, clinical and molecular profiles, treatment received, and outcomes including real-world event free survival (rwEFS), real-world progression free survival (rwPFS), and overall survival (OS) were assessed.

resultsThe study included 121 patients with RET fusion-positive NSCLC, comprising 80 early-stage and 58 advanced-stage patients. High biomarker testing rates were observed at diagnosis (75% for early-stage, 78% for advanced-stage). RET testing was often conducted via tissue samples (95.9%) and next-generation sequencing (89.3%). KIF5B (57.0%) and CCDC6 (20.7%) were the most common gene fusion partners. The most frequent oncogenic mutations were TP53 (15.7%) and EGFR (6.6%). Platinum-based chemotherapy was the most common first-line treatment among advanced-stage patients. Median rwPFS was 9.22 months for advanced-stage patients on first-line chemotherapy, and median OS was 30.7 months for all advanced-stage patients. The 2-year rwEFS rate for early-stage patients was 86.0%, with a median OS of 91.9 months.

conclusionsThe study observed high biomarker testing rates at initial diagnosis for early- and advanced-stage RET fusion-positive NSCLC patients in China. The heterogeneous treatment pattern of advanced patients suggests the need for more precise, evidence-based treatment to guide clinical decisions. Given the existing therapeutic regimens fall short of adequately addressing treatment needs, targeted therapies are essential to improve outcomes.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-retAdultAgedBiomarkers, TumorChinaFemaleHumansMaleMiddle AgedOncogene Proteins, FusionRetrospective StudiesTreatment OutcomeBiomarkers, TumorOncogene Proteins, FusionProto-Oncogene Proteins c-retRET protein, humanDiagnosis patternsNon-small cell lung cancerReal-world contextRET fusionsTreatment patterns

Identifiers

PMID39316291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.